New drug to treat chronic kidney disease gets approval

Subject: Science and tech

Section: Health

Context:

The Central Drugs Standard Control Organisation (CDSCO) has approved Jardiance (empagliflozin) 10mg tablets for end-stage kidney and cardiovascular diseases.

More on news:

It will reduce the risk of sustained decline in patients with end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
Jardiance is not recommended for the treatment of CKD in patients with polycystic kidney disease.
According to CDSCO, this indication approval allows nephrologists and cardiologists to use Jardiance 10mg tablets for the treatment of CKD in eligible patients.

About Empagliflozin:

It is used to treat type 2 diabetes.
It works in the kidneys to prevent absorption of glucose (blood sugar).
This helps lower the blood sugar level.
Empagliflozin does not help patients who have insulin-dependent or type 1 diabetes.